Companion diagnostic biomarker composition and companion diagnostic kit containing the same

A companion diagnostic biomarker composition using complement C7 and other proteins provides high-accuracy prediction of therapeutic responses to PD-1 and PD-L1 immune checkpoint inhibitors, addressing inaccuracies in conventional tests and improving treatment selection for cancer patients.

JP7593669B2Active Publication Date: 2024-12-03INNOBATION BIO CO LTD
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2022535227
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2020-05-11
Filing Date
2020-06-26
Publication Date
2024-12-03
Estimated Expiration
2040-06-26

AI Technical Summary

Technical Problem

Conventional companion diagnostic tests for PD-1 and PD-L1 immune checkpoint inhibitors face challenges in accurately predicting therapeutic response due to variability in tissue sampling and prolonged result times, leading to reduced accuracy in selecting patient groups for effective treatment.

Method used

A companion diagnostic biomarker composition comprising complement component C7 and additional proteins (HRG, AZGP1, C5, IGKV4-1, MAN1A, A2M, SPP1, HYOU1) is developed, allowing for high-accuracy prediction of therapeutic response through quantitative analysis using methods like mass spectrometry and immunoassays, distinguishing between responsive and non-responsive patient groups.

Benefits of technology

The biomarker composition achieves precise identification of patient groups suitable for PD-1 and PD-L1 immune checkpoint inhibitor treatments, enhancing treatment efficacy by accurately predicting therapeutic responses and reducing variability.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007593669000005
    Figure 0007593669000005
  • Figure 0007593669000006
    Figure 0007593669000006
  • Figure 0007593669000007
    Figure 0007593669000007
Patent Text Reader

Abstract

The present invention relates to a companion diagnostic biomarker composition and a companion diagnostic kit including the same, specifically to a companion diagnostic biomarker composition for predicting therapeutic response to one or more immune checkpoint inhibitors, including a PD-1 immune checkpoint inhibitor and a PD-L1 immune checkpoint inhibitor, and a companion diagnostic kit including the same. The present invention has the effect of enabling prediction of therapeutic response to one or more immune checkpoint inhibitors, including a PD-1 immune checkpoint inhibitor and a PD-L1 immune checkpoint inhibitor, through not only companion diagnosis via cancer patient tissue but also proteome analysis in the blood of cancer patients.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a companion diagnostic biomarker composition and a companion diagnostic kit containing the same, specifically to a companion diagnostic biomarker composition for predicting therapeutic response to any one or more immune checkpoint inhibitors selected from the group consisting of PD-1 immune checkpoint inhibitors (PD-1 Checkpoint Inhibitors) and PD-L1 immune checkpoint inhibitors (PD-L1 Checkpoint Inhibitors), and a companion diagnostic kit containing the same. [Background technology]

[0002] Companion diagnosis is a diagnostic technique to predict a patient's responsiveness to a specific drug treatment. To overcome the shortcomings of most conventional anti-cancer drugs, which act on both cancer cells and normal cells and have significant side effects, targeted anti-cancer drugs that selectively attack specific target proteins and immune anti-cancer drugs that activate the body's suppressed immune system to kill cancer cells have been developed.

[0003] However, targeted anticancer drugs are effective only in cancer patients with specific target proteins, even if they have the same type of cancer. If patients with such target proteins are not selected, the therapeutic efficiency is very low. In addition, targeted anticancer drugs rely on cell growth and proliferation inhibition rather than cell death, so there is a high possibility of resistance developing due to continuous drug administration over a long period of time. Therefore, it is necessary to select patients who will respond to the drug through analysis of the anticancer drug target before administering the drug.

[0004] Immunotherapy for cancer is effective in treating cancer by enhancing the specificity, memory, and adaptability of the immune system. In other words, it uses the body's immune system to attack only cancer cells with minimal side effects, and by utilizing the immune system's memory and adaptability, patients who respond to immunotherapy for cancer can achieve sustained anticancer effects. However, since the degree of anticancer effect of immunotherapy for cancer varies depending on the specific patient, even if the patient has the same type of cancer, a companion diagnostic is needed to predict the response of the patient to immunotherapy for cancer.

[0005] A companion diagnostic biomarker is used to select a patient group that will respond to a specific drug treatment. Here, the companion diagnostic biomarker is an indicator for predicting a patient's responsiveness to a specific drug treatment in advance, and may include proteins, DNA, RNA, metabolic substances, etc. In other words, in the case of a specific disease or cancer, it means a marker that can distinguish between normal and pathological states, predict a treatment response, and can be objectively measured.

[0006] Meanwhile, with pharmaceutical companies reducing new drug development costs and increasing demand for targeted anticancer drugs, the global companion diagnostics market is estimated to grow at 18% annually between 2013 and 2019, reaching approximately $5.8 billion in 2019.

[0007] For example, Roche, a multinational pharmaceutical company, acquired Genentech, which developed the first breast cancer targeted anticancer drug, Herceptin, and its companion diagnostic kit, Herceptest, to begin companion diagnostic-based anticancer drug treatment.

[0008] Companion diagnostic kits include those that check for overexpression of specific proteins through immunohistochemistry tests such as DAKO and HercepTest, those that check for gene amplification of specific genes through FISH or CISH tests using DNA probes such as Ventana Medical Systems and INFORM HER-2 / NEU, and those that check for the presence or absence of mutations in biomarker genes using genetic techniques such as q-PCR such as Roche Diagnostics and cobas EGFR mutation test.

[0009] Meanwhile, immune anticancer drugs can be divided into passive and active immunotherapy, and passive immunotherapy includes immune checkpoint inhibitors, immune cell therapy, and therapeutic antibodies. Immune checkpoint inhibitors are drugs that block the activation of immune checkpoint proteins involved in T cell inhibition, activating T cells to attack cancer cells, and include CTLA-4, PD-1, and PD-L1 immune checkpoint inhibitors.

[0010] PD-1 immune checkpoint inhibitors are second-generation immunotherapy drugs; pembrolizumab (KEYTRUDA®) developed by Merck and nivolumab (OPDIVO®) developed by Ono Pharmaceutical and BMS were approved by the U.S. FDA in 2014, and atezolizumab (Tecentriq®), a PD-L1 immune checkpoint inhibitor developed by Genentech / Roche, was approved by the U.S. FDA in 2016.

[0011] It has an action mechanism of enhancing immunity by using human anti-PD-1 monoclonal antibodies or human anti-PD-L1 monoclonal antibodies that block PD-1-mediated lymphocyte negative regulation (interaction between PD-1 and PD-L1 and PD-L2 ligands), thereby recognizing cancer cells as foreign bodies and eliminating them.

[0012] Pembrolizumab is FDA approved for the treatment of malignant melanoma, non-small cell lung cancer, head and neck squamous cell cancer, classical Hodgkin lymphoma, urothelial carcinoma, all solid tumors that exhibit mismatch repair deficiency (dMMR) or microsatellite instability-High (MSI-High), and gastric and gastroesophageal junction adenocarcinoma. Nivolumab has shown clinical benefit in clinical studies for a variety of advanced cancers and has recently been approved as a drug for melanoma, non-small cell lung cancer, renal cancer, and other cancers and is widely used.

[0013] In addition, there is a companion diagnostic test called the "PD-L1 IHC 22C3 pharmDx test," which is used to determine whether pembrolizumab effectively exerts an anti-cancer effect as an immuno-anti-cancer drug in a specific patient. The PD-L1 IHC 22C3 pharmDx test is an immunohistochemistry (IHC) method used to observe the PD-L1 expression rate of biopsy cancer cells using DAKO's PD-L1 IHC 22C3 pharmDx product, and is used to select patients suitable for pembrolizumab treatment. Similarly, companion diagnostic tests for nivolumab include the "VENTANA PD-L1 (SP263) Assay test" and the "PD-L1 IHC 28-8 pharmDx test."

[0014] However, these conventional companion diagnostic tests measure PD-L1 expression by removing a portion of the patient's tumor tissue (405 μm). The level of PD-L1 expression varies depending on the patient's tissue sampling, and it takes more than three weeks to obtain the analysis results. Not only does this test have some drawbacks, but it also has some limitations in the accuracy of selecting patients who will respond to immune-mediated anti-cancer drugs.

[0015] Accordingly, in order to overcome the technical limitations of such companion diagnostic tests, the present inventors have developed a companion diagnostic biomarker composition and a companion diagnostic kit including the same for predicting therapeutic response to one or more immune checkpoint inhibitors, including PD-1 checkpoint inhibitors and PD-L1 checkpoint inhibitors, through proteomic analysis on blood as well as measurement in tissues. Summary of the Invention [Problem to be solved by the invention]

[0016] In order to solve the above-mentioned problems, the present invention aims to provide a biomarker composition for companion diagnostics for predicting therapeutic response to one or more immune checkpoint inhibitors, including PD-1 checkpoint inhibitors and PD-L1 checkpoint inhibitors, through proteome analysis in the blood of cancer patients as well as companion diagnostics through the tissues of cancer patients, and a companion diagnostic kit including the same.

[0017] Another object of the present invention is to provide a biomarker composition for companion diagnostics for predicting therapeutic response to any one or more of PD-1 immune checkpoint inhibitors and PD-L1 immune checkpoint inhibitors, which can accurately distinguish between a patient group that responds to anti-cancer treatment using any one or more of immune checkpoint inhibitors, including PD-1 immune checkpoint inhibitors and PD-L1 immune checkpoint inhibitors, and a companion diagnostic kit including the same.

[0018] Another object of the present invention is to provide a companion diagnostic biomarker composition that can more accurately identify patient groups suitable for anti-cancer treatment using one or more immune checkpoint inhibitors, including PD-1 immune checkpoint inhibitors and PD-L1 immune checkpoint inhibitors, and a companion diagnostic kit including the same. [Means for solving the problem]

[0019] In order to achieve the above-mentioned object, the companion diagnostic biomarker composition according to the present invention is characterized in that it contains Complement Component C7 and predicts the reactivity of one or more immune checkpoint inhibitors, including a PD-1 (Programmed Cell Death Protein 1) immune checkpoint inhibitor and a PD-L1 (Programmed Death-Ligand 1) immune checkpoint inhibitor, against cancer cells.

[0020] Here, the companion diagnostic biomarker composition may further comprise one or more biomarkers selected from the group consisting of HRG (Histidine-Rich Glycoprotein), AZGP1 (Zinc-Alpha-2-Glycoprotein), Complement Component C5 (Complement Component C5), IHKV4-1 (Immunoglobulin Kappa Variable 4-1), MAN1A (Mannosyl-Oligosaccharide 1,2-Alpha-Mannosidase 1A), A2M (Alpha-2-Macroglobulin), SPP1 (Osteopontin), and HYOU1 (Hypoxia Up-Regulated Protein 1).

[0021] Here, the amount of the complement C7 protein can be measured through quantitative analysis.

[0022] Here, the amount of the complement C7 protein can be measured by any one of the following methods: protein mass spectrometry, protein chip analysis, immunoassay, ligand binding assay, MALDI-TOF (Matrix Desorption / Ionization Time of Flight Mass Spectrometry) analysis, SELDI-TOF (Sulface Enhanced Laser Desorption / Ionization Time of Flight Mass Spectrometry) analysis, radioimmunoassay, radial immunodiffusion, Ouchterlony immunodiffusion, rocket immunoelectrophoresis, tissue immunostaining, complement fixation analysis, two-dimensional electrophoresis, liquid chromatography-mass spectrometry (LC-MS), LC-MS / MS (Liquid Chromatography-Mass Spectrometry / Mass Spectrometry), Western blot, and ELISA (Enzyme Linked Immunosorbent assay).

[0023] Here, the amount of complement C7 protein can be reduced in a patient group that responds to anti-cancer treatment using the PD-1 immune checkpoint inhibitor, compared to a patient group that does not respond to anti-cancer treatment using the PD-1 immune checkpoint inhibitor.

[0024] Here, the amount of complement C7 protein may be increased in a non-responder patient group that is not effective against anti-cancer treatment using the PD-1 immune checkpoint inhibitor, compared to a responder patient group that is effective against anti-cancer treatment using the PD-1 immune checkpoint inhibitor.

[0025] Here, the amount of complement C7 protein can be reduced in a patient group that responds to anti-cancer treatment using the PD-L1 immune checkpoint inhibitor, compared to a patient group that does not respond to anti-cancer treatment using the PD-L1 immune checkpoint inhibitor.

[0026] Here, the amount of complement C7 protein may be increased in a non-responder patient group that is not effective against anti-cancer treatment using the PD-L1 immune checkpoint inhibitor, compared to a responder patient group that is effective against anti-cancer treatment using the PD-L1 immune checkpoint inhibitor.

[0027] Here, the cutoff value for the protein amount of the complement C7 may be within the range of 100 to 110 μg / mL.

[0028] Here, when the protein amount of the complement C7 is equal to or greater than the cutoff value, the reactivity of the PD-1 immune checkpoint inhibitor to the cancer cells may be low.

[0029] Here, when the protein amount of the complement C7 is less than the cutoff value, the reactivity of the PD-1 immune checkpoint inhibitor to the cancer cells may be high.

[0030] Here, when the protein amount of the complement C7 is equal to or greater than the cutoff value, the reactivity of the PD-L1 immune checkpoint inhibitor to the cancer cells may be low.

[0031] Here, when the protein amount of the complement C7 is less than the cutoff value, the reactivity of the PD-L1 immune checkpoint inhibitor to the cancer cells may be high.

[0032] Here, the companion diagnostic biomarker composition may be extracted from any one selected from the group consisting of blood, serum, plasma, and tissue.

[0033] Here, the companion diagnostic biomarker composition may be extracted from blood.

[0034] Here, the companion diagnostic biomarker composition may be extracted from a tissue.

[0035] Here, the companion diagnostic biomarker composition may further contain PD-L1 (Programmed Death-Ligand 1) protein.

[0036] Here, the cancer cells may be cancer cells corresponding to a carcinoma that specifically reacts to one or more immune checkpoint inhibitors selected from the group consisting of a PD-1 immune checkpoint inhibitor and a PD-L1 immune checkpoint inhibitor.

[0037] Here, the cancer cells may be cancer cells corresponding to any one of the cancer types selected from the group consisting of lung cancer, liver cancer, gastric cancer, gastroesophageal junction adenocarcinoma, skin melanoma, head and neck cancer, bone cancer, pancreatic cancer, skin cancer, uterine cancer, ovarian cancer, rectal cancer, colon cancer, colon cancer, breast cancer, uterine sarcoma, trumpeting duct carcinoma, endometrial carcinoma, cervical carcinoma, vaginal carcinoma, vulvar carcinoma, esophageal cancer, laryngeal cancer, small intestine cancer, thyroid cancer, parathyroid cancer, soft tissue sarcoma, urethral cancer, penile cancer, prostate cancer, chronic or acute leukemia, solid tumor of childhood, differentiated lymphoma, bladder cancer, kidney cancer, renal cell carcinoma, renal pelvic carcinoma, primary central nervous system lymphoma, spinal cord tumor, brain stem glioma, and pituitary adenoma.

[0038] Here, the cancer cells may be cancer cells corresponding to lung cancer or liver cancer.

[0039] Here, the companion diagnostic biomarker composition may be administered simultaneously or sequentially in combination with any one or more of the PD-1 immune checkpoint inhibitor and the PD-L1 immune checkpoint inhibitor.

[0040] On the other hand, the companion diagnostic kit according to the present invention may contain the companion diagnostic biomarker composition according to the present invention. Effect of the Invention

[0041] The companion diagnostic biomarker composition of the present invention and the companion diagnostic kit including the same as described above have the effect of predicting the therapeutic response to one or more immune checkpoint inhibitors selected from PD-1 immune checkpoint inhibitors and PD-L1 immune checkpoint inhibitors through proteome analysis in the blood of cancer patients as well as companion diagnosis through the tissue of cancer patients.

[0042] In addition, the biomarker composition for companion diagnostics according to the present invention and the companion diagnostic kit including the same have the advantage of being highly accurate in distinguishing between a responder patient group who shows efficacy and a non-responder patient group who does not show efficacy in anti-cancer treatment using one or more immune checkpoint inhibitors selected from PD-1 immune checkpoint inhibitors and PD-L1 immune checkpoint inhibitors.

[0043] In addition, the companion diagnostic biomarker composition according to the present invention and the companion diagnostic kit including the same have the effect of more accurately identifying patient groups suitable for anti-cancer treatment using one or more immune checkpoint inhibitors selected from the group consisting of PD-1 immune checkpoint inhibitors and PD-L1 immune checkpoint inhibitors. [Brief description of the drawings]

[0044] Figures 1a to 1i are graphs showing the companion diagnostic results predicting the reactivity of one or more of the immune checkpoint inhibitors, namely PD-1 immune checkpoint inhibitors and PD-L1 immune checkpoint inhibitors, against cancer cells for nine companion diagnostic biomarkers, namely complement C7, HRG, AZGP1, complement C5, IGKV4-1, MAN1A, A2M, SPP1 and HYOU1, respectively. FIG. 2a is a graph showing the results of a companion diagnostic test for 10 lung cancer patients using a companion diagnostic biomarker composition according to one embodiment of the present invention. FIG. 2b is a graph showing the results of a companion diagnostic test for 11 lung cancer patients using a companion diagnostic biomarker composition according to one embodiment of the present invention. FIG. 2c is a graph showing the results of companion diagnostic tests for a total of 21 lung cancer patients using a companion diagnostic biomarker composition according to one embodiment of the present invention. FIG. 3 is a graph showing the results of a companion diagnostic test when the biomarker composition for companion diagnostics according to one embodiment of the present invention further contains the biomarker IGKV4-1. BEST MODE FOR CARRYING OUT THEINVENTION

[0045] The companion diagnostic biomarker composition of the present invention contains Complement Component C7 and is characterized in that it predicts the reactivity of cancer cells to one or more immune checkpoint inhibitors, including a PD-1 checkpoint inhibitor and a PD-L1 checkpoint inhibitor. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0046] The terms used in this application are merely used to describe specific examples. Thus, for example, singular expressions include plural expressions unless the context clearly requires singularity. It should be noted that the terms "include" or "comprise" used in this application are used to clearly indicate the presence of features, steps, functions, components, or combinations thereof described in the specification, and are not used to preliminarily exclude the presence of other features, steps, functions, components, or combinations thereof.

[0047] Meanwhile, unless otherwise specifically defined, all terms used herein should be considered to have the same meaning as that commonly understood by a person having ordinary skill in the art to which the present invention pertains. Therefore, unless clearly defined herein, specific terms should not be construed as having an overly ideal or formal meaning.

[0048] As used herein, the term "companion diagnosis" refers to a diagnostic technique for predicting in advance the responsiveness of a patient to a particular drug treatment.

[0049] As used herein, the term "companion diagnostic biomarker" refers to an indicator for predicting a patient's responsiveness to a specific drug treatment, and may include proteins, DNA, RNA, metabolic substances, etc. In other words, in the case of a specific disease or cancer, it refers to a marker that can distinguish between normal and pathological states, predict a treatment response, and can be objectively measured.

[0050] As used herein, the term "immune checkpoint inhibitor" is synonymous with immune checkpoint inhibitor, and refers to a drug that blocks the activation of immune checkpoint proteins involved in T cell inhibition, thereby activating T cells to attack cancer cells. In the present specification, one or more immune checkpoint inhibitors, including PD-1 immune checkpoint inhibitors and PD-L1 immune checkpoint inhibitors, are disclosed. The PD-1 immune checkpoint inhibitor or PD-L1 immune checkpoint inhibitor may be, but is not limited to, pembrolizumab, nivolumab, or atezolizumab.

[0051] <Biomarker Composition for Companion Diagnostics> As a result of research to solve the above-mentioned problems, the present inventors have come up with the following invention: This specification discloses a biomarker composition for companion diagnostics, which contains Complement Component C7 and predicts the reactivity of cancer cells to one or more immune checkpoint inhibitors, including a PD-1 checkpoint inhibitor and a PD-L1 checkpoint inhibitor.

[0052] The body's immune function regulates overall T cell function through the regulation of co-stimulatory and co-inhibitory signals in addition to antigen recognition. Thus, immune cells detect tumor-specific antigens expressed by changes such as mutations in cancer cells and eliminate the cancer cells. However, to avoid immune attacks, cancer cells try to change the tumor microenvironment to inhibit immune function or to escape immune cells through T cell immune tolerance or immuno-editing. One such evasion strategy is to inhibit T cell function by changing the function of immune checkpoints; that is, immune barriers are proteins that prevent the destruction of cancer cells, and cancers activate inhibitory immune checkpoints to avoid T cell attacks.

[0053] The immune response of T cells is a highly sophisticated process in which the interactions between costimulatory receptors, which act as accelerators, costimulatory receptors, which act as brakes, and ligands that bind to each receptor operate in a visual-spatial manner. Meanwhile, PD-1 on T cells regulates T cell function in peripheral tissues through PD-L1 / PD-L2 on cancer cells. That is, when PD-L1 on cancer cells binds to PD-1 on T cells, T cells lose their function and die. Unlike conventional immunotherapeutic agents such as cytokine therapeutics and anti-cancer vaccines, immune checkpoint inhibitors bind to the binding sites of cancer cells and T cells to block immune evasion signals, preventing the formation of immunological synapses, and thus allowing T cells that are not hindered by immune evasion to destroy cancer cells. That is, when PD-1 antibodies or PD-L1 antibodies bind in advance between the binding sites of PD-L1 and PD-1, the immune evasion signals are blocked, and T cells that have not received the immune evasion signals kill cancer cells.

[0054] The companion diagnostic biomarker composition according to the present invention includes Complement Component C7, which can be used as a companion diagnostic biomarker for predicting the reactivity of cancer cells to one or more immune checkpoint inhibitors, including a PD-1 checkpoint inhibitor and a PD-L1 checkpoint inhibitor.

[0055] Complement component C7 contained in the biomarker composition for companion diagnostics according to the present invention acts as a biomarker to regulate the antigen-antibody immune response of the human body and dissolves pathogens by forming a membrane attack complex (MAC). According to the Gene Ontology classification, it is a protein involved in immune response and dissolution, and its gene information can be found from GeneBank Accession No., Uniprot, etc. However, no direct relevance of the complement C7 to predicting the reactivity of PD-1 immune checkpoint inhibitors or PD-L1 immune checkpoint inhibitors to cancer cells has been disclosed anywhere.

[0056] Furthermore, the companion diagnostic biomarker composition according to the present invention may further comprise a preparation for measuring the protein amount of the complement C7.

[0057] Meanwhile, the companion diagnostic biomarker composition according to the present invention may further comprise one or more biomarkers selected from the group consisting of HRG (Histidine-Rich Glycoprotein), AZGP1 (Zinc-Alpha-2-Glycoprotein), Complement Component C5 (Complement Component C5), IHKV4-1 (Immunoglobulin Kappa Variable 4-1), MAN1A (Mannosyl-Oligosaccharide 1,2-Alpha-Mannosidase 1A), A2M (Alpha-2-Macroglobulin), SPP1 (Osteopontin) and HYOU1 (Hypoxia Up-Regulated Protein 1).

[0058] Histidine-Rich Glycoprotein (HRG), Zinc-Alpha-2-Glycoprotein (AZGP1), Complement Component C5 (Complement Component C5), Immunoglobulin Kappa Variable 4-1 (IHKV4-1), Mannosyl-Oligosaccharide 1,2-Alpha-Mannosidase 1A (MAN1A), Alpha-2-Macroglobulin (A2M), Osteopontin (SPP1), and Hypoxia Up-Regulated Protein 1 (HYOU1), which are included in the biomarker composition for companion diagnostics according to the present invention, function as biomarkers that regulate the antigen-antibody immune response of the human body, and are proteins involved in immune response and lysis according to the Gene Ontology classification, and their gene information can be found from GeneBank Accession No., Uniprot, etc. However, no direct correlation between HRG, AZGP1, complement C5, IHKV4-1, MAN1A, A2M and HYOU1 and the prediction of the responsiveness of cancer cells to PD-1 immune checkpoint inhibitors or PD-L1 immune checkpoint inhibitors has been disclosed anywhere.

[0059] Furthermore, the companion diagnostic biomarker composition according to the present invention may further comprise a preparation for measuring the protein amount of any one or more biomarkers selected from the group consisting of HRG, AZGP1, complement C5, IHKV4-1, MAN1A, A2M and HYOU1.

[0060] Meanwhile, in the biomarker composition for companion diagnostics according to the present invention, the protein amount of the complement C7 can be measured through a quantitative analysis. Also, the protein amount of the complement C7 can be measured through a qualitative analysis, a quantitative analysis, or both a qualitative analysis and a quantitative analysis through a proteome analysis method.

[0061] Similarly, in the biomarker composition for companion diagnostics according to the present invention, the protein amount of one or more biomarkers selected from the group consisting of HRG, AZGP1, complement C5, IHKV4-1, MAN1A, A2M and HYOU1 can be measured through quantitative analysis. In addition, the protein amount of one or more biomarkers selected from the group consisting of HRG, AZGP1, complement C5, IHKV4-1, MAN1A, A2M and HYOU1 can be qualitatively, quantitatively or both qualitatively and quantitatively analyzed through proteome analysis.

[0062] In the present specification, the term "protein amount" refers to a process of treating a cancer patient with a cancer that specifically reacts to one or more of the PD-1 immune checkpoint inhibitors and the PD-L1 immune checkpoint inhibitors with one or more of the PD-1 immune checkpoint inhibitors and determining whether or not a protein is present in the blood of the cancer patient and the degree of measurement. The amount of the protein can be determined using an antibody, an interacting protein, a ligand, nanoparticles, or an aptamer that specifically binds to the protein or peptide fragment, and may include any detection means that has a specific affinity for the protein or peptide fragment. More preferably, the amount of the protein itself can be measured without using an antibody, an interacting protein, a ligand, nanoparticles, or an aptamer.

[0063] In the biomarker composition for companion diagnostics according to the present invention, the method for measuring or comparatively analyzing the amount of protein is preferably any one selected from the group consisting of protein mass spectrometry, protein chip analysis, immunoassay, ligand binding assay, MALDI-TOF (Matrix Desorption / Ionization Time of Flight Mass Spectrometry) analysis, SELDI-TOF (Sulface Enhanced Laser Desorption / Ionization Time of Flight Mass Spectrometry) analysis, radioimmunoassay, radial immunodiffusion, Ouchterlony immunodiffusion, rocket immunoelectrophoresis, tissue immunostaining, complement fixation analysis, two-dimensional electrophoresis analysis, liquid chromatography-mass spectrometry (LC-MS), LC-MS / MS (Liquid Chromatography-Mass Spectrometry / Mass Spectrometry), Western blot, and ELISA (Enzyme Linked Immunosorbent assay), but is not limited thereto.

[0064] Meanwhile, the preparation for measuring the amount of the complement C7 protein in the biomarker composition for companion diagnostics according to the present invention may include any one or more selected from the group consisting of an antibody that specifically binds to the complement C7 protein, an interacting protein, a ligand, a nanoparticle, and an aptamer. The antibody means a specific protein molecule that is labeled with an antigenic site, but for the purposes of the present invention, the antibody refers to an antibody that specifically binds to the complement C7 protein, and includes all of polyclonal antibodies, monoclonal antibodies, and recombinant antibodies. The antibody can be easily produced using techniques that are widely known in the art. In addition, the antibody includes not only a complete form having two full-length light chains and two full-length heavy chains, but also a functional fragment of the antibody molecule. The functional fragment of the antibody molecule means a fragment that has at least an antigen binding function, and includes Fab, F(ab'), F(ab')2, and Fv.

[0065] Furthermore, in the companion diagnostic biomarker composition according to the present invention, the preparation for measuring the protein amount of one or more biomarkers selected from the group consisting of HRG, AZGP1, complement C5, IHKV4-1, MAN1A, A2M and HYOU1 may comprise one or more selected from the group consisting of antibodies, interacting proteins, ligands, nanoparticles and aptamers that specifically bind to the protein of one or more biomarkers selected from the group consisting of HRG, AZGP1, complement C5, IHKV4-1, MAN1A, A2M and HYOU1.

[0066] As used herein, the term "aptamer" refers to a biopolymer in the form of single or double helix DNA or RNA that inhibits protein interactions through three-dimensional binding with specific target proteins, and has the characteristic of binding to a variety of target molecules. In general, an aptamer can be a small nucleic acid of 15 to 50 bases in length that folds into a defined secondary and tertiary structure, such as a stem-loop structure. An aptamer can be a nucleic acid that folds into a defined secondary or tertiary structure, such as a stem-loop structure, and can be used to bind to a wide variety of target molecules. -6 , 10 -8 , 10 -10, or 10 -12 It is preferable that the aptamer binds to the target highly or low expressed protein with a lower kd. The aptamer can bind to the highly or low expressed protein with a very high degree of specificity, and the aptamer can be composed of a number of ribonucleotide units, deoxyribonucleotide units, or a mixture of two types of nucleotide residues. The aptamer may further include one or more modified bases, sugars, or phosphate backbone units.

[0067] Meanwhile, complement C7 contained in the biomarker composition for companion diagnostics according to the present invention is characterized in that the amount of protein is decreased in a responder group of patients who are effective against anti-cancer treatment using PD-1 immune checkpoint inhibitors, compared to a non-responder group of patients who are not effective against anti-cancer treatment using PD-1 immune checkpoint inhibitors.

[0068] Conversely, complement C7 contained in the biomarker composition for companion diagnostics according to the present invention is characterized in that the protein amount is increased in a non-responder patient group that does not show an effect on anti-cancer treatment using PD-1 immune checkpoint inhibitors compared to a responder patient group that shows an effect on anti-cancer treatment using PD-1 immune checkpoint inhibitors.

[0069] In addition, the complement C7 contained in the biomarker composition for companion diagnostics according to the present invention is characterized in that the protein amount is decreased in a responder group of patients who are effective against anti-cancer treatment using PD-L1 immune checkpoint inhibitors, compared to a non-responder group of patients who are not effective against anti-cancer treatment using PD-L1 immune checkpoint inhibitors.

[0070] Conversely, complement C7 contained in the biomarker composition for companion diagnostics according to the present invention is characterized in that the protein amount is increased in a non-responder patient group that does not show an effect on anti-cancer treatment using PD-L1 immune checkpoint inhibitors compared to a responder patient group that shows an effect on anti-cancer treatment using PD-L1 immune checkpoint inhibitors.

[0071] In the biomarker composition for companion diagnostics according to the present invention, the cutoff value for the protein amount of the complement C7 is preferably within the range of 90 to 120 μg / mL, more specifically, more preferably within the range of 100 to 110 μg / mL, but is not limited thereto. The cutoff value can be arbitrarily set by the practitioner performing the companion diagnostic test depending on the number of cancer patients to be measured. The cutoff value for the protein amount of the complement C7 is a standard value for judging the reactivity of any one or more immune checkpoint inhibitors of the PD-1 immune checkpoint inhibitor and the PD-L1 immune checkpoint inhibitor to cancer cells, and more specifically, means a standard value for classifying patients into a responder group that shows an effect on anti-cancer treatment through any one or more immune checkpoint inhibitors of the PD-1 immune checkpoint inhibitor and the PD-L1 immune checkpoint inhibitor, and a non-responder group that does not show an effect.

[0072] Here, when the protein amount of the complement C7 is equal to or more than the cutoff value, the reactivity of the PD-1 immune checkpoint inhibitor to the cancer cells may be low. That is, when the protein amount of the complement C7 is equal to or more than the cutoff value as a result of performing a companion diagnosis for predicting the reactivity of the PD-1 immune checkpoint inhibitor to the cancer cells using the biomarker composition for companion diagnosis according to the present invention, it means that the reactivity of the PD-1 immune checkpoint inhibitor to the cancer cells is low. In this case, the patient can be classified into a non-responder group that does not show an effect in anti-cancer treatment using a PD-1 immune checkpoint inhibitor.

[0073] On the other hand, when the protein amount of the complement C7 is less than the cutoff value, the reactivity of the PD-1 immune checkpoint inhibitor to the cancer cells may be high. That is, when the protein amount of the complement C7 is less than the cutoff value as a result of performing a companion diagnosis for predicting the reactivity of the PD-1 immune checkpoint inhibitor to the cancer cells using the biomarker composition for companion diagnosis according to the present invention, it means that the reactivity of the PD-1 immune checkpoint inhibitor to the cancer cells is high. In this case, the patient can be classified into a responder group that shows an effect of anti-cancer treatment using a PD-1 immune checkpoint inhibitor.

[0074] When the protein amount of the complement C7 is equal to or greater than the cutoff value, the reactivity of the PD-L1 immune checkpoint inhibitor to the cancer cells may be low. That is, when the protein amount of the complement C7 is equal to or greater than the cutoff value as a result of performing a companion diagnosis for predicting the reactivity of the PD-L1 immune checkpoint inhibitor to the cancer cells using the biomarker composition for companion diagnostics according to the present invention, the reactivity of the PD-L1 immune checkpoint inhibitor to the cancer cells is low. In this case, the patient can be classified into a non-responder group that does not show any effect in anti-cancer treatment using a PD-L1 immune checkpoint inhibitor.

[0075] On the other hand, when the protein amount of the complement C7 is less than the cutoff value, the reactivity of the PD-L1 immune checkpoint inhibitor to the cancer cells may be high. That is, when the protein amount of the complement C7 is less than the cutoff value as a result of performing a companion diagnosis for predicting the reactivity of the PD-L1 immune checkpoint inhibitor to the cancer cells using the biomarker composition for companion diagnosis according to the present invention, it means that the reactivity of the PD-L1 immune checkpoint inhibitor to the cancer cells is high. In this case, the patient can be classified into a responder group that shows an effect on anti-cancer treatment through the PD-L1 immune checkpoint inhibitor. Specific details in this regard will be described in detail in the following {Examples and Evaluation}.

[0076] Meanwhile, any one or more biomarkers selected from the group consisting of HRG, AZGP1, complement C5, IHKV4-1, MAN1A, A2M and HYOU1 contained in the biomarker composition for companion diagnostics according to the present invention are characterized in that the amount of protein is decreased in a responder patient group that is effective against anti-cancer treatment using PD-1 immune checkpoint inhibitors and / or PD-L1 immune checkpoint inhibitors, compared to a non-responder patient group that is not effective against anti-cancer treatment using PD-1 immune checkpoint inhibitors and / or PD-L1 immune checkpoint inhibitors.

[0077] Conversely, any one or more biomarkers selected from the group consisting of HRG, AZGP1, complement C5, IHKV4-1, MAN1A, A2M and HYOU1 contained in the biomarker composition for companion diagnostics according to the present invention are characterized in that the protein amount is increased in a non-responder patient group that is not effective against anti-cancer treatment via PD-1 immune checkpoint inhibitors and / or PD-L1 immune checkpoint inhibitors compared to a responder patient group that is effective against anti-cancer treatment via PD-1 immune checkpoint inhibitors and / or PD-L1 immune checkpoint inhibitors.

[0078] In addition, in the biomarker composition for companion diagnostics according to the present invention, the cutoff value for the protein amount of any one or more biomarkers selected from the group consisting of HRG, AZGP1, complement C5, IHKV4-1, MAN1A, A2M and HYOU1 is preferably within the range of 50 to 150 ug / mL, but is not limited thereto. The cutoff value for the protein amount of any one or more biomarkers selected from the group consisting of HRG, AZGP1, complement C5, IHKV4-1, MAN1A, A2M and HYOU1 is a standard value for judging the reactivity of any one or more immune checkpoint inhibitors of PD-1 immune checkpoint inhibitors and PD-L1 immune checkpoint inhibitors to cancer cells, and more specifically, means a standard value for classifying patients into a responder group that shows an effect on anti-cancer treatment through any one or more immune checkpoint inhibitors of PD-1 immune checkpoint inhibitors and PD-L1 immune checkpoint inhibitors, and a non-responder group that does not show an effect.

[0079] Here, when the protein amount of any one or more biomarkers selected from the group consisting of HRG, AZGP1, complement C5, IHKV4-1, MAN1A, A2M, and HYOU1 is equal to or greater than the cutoff value, the reactivity of the PD-1 immune checkpoint inhibitor and / or the PD-L1 immune checkpoint inhibitor to the cancer cells may be low. That is, when the protein amount of any one or more biomarkers selected from the group consisting of HRG, AZGP1, complement C5, IHKV4-1, MAN1A, A2M, and HYOU1 is equal to or greater than the cutoff value as a result of performing companion diagnosis for predicting the reactivity of a PD-1 immune checkpoint inhibitor and / or a PD-L1 immune checkpoint inhibitor to cancer cells using the biomarker composition for companion diagnosis according to the present invention, the reactivity of the PD-1 immune checkpoint inhibitor and / or the PD-L1 immune checkpoint inhibitor to the cancer cells is low. In this case, patients can be classified as non-responders who do not respond to anti-cancer treatment via PD-1 immune checkpoint inhibitors and / or PD-L1 immune checkpoint inhibitors.

[0080] On the other hand, when the protein amount of one or more biomarkers selected from the group consisting of HRG, AZGP1, complement C5, IHKV4-1, MAN1A, A2M and HYOU1 is less than the cutoff value, the cancer cells may be highly responsive to the PD-1 immune checkpoint inhibitor and / or PD-L1 immune checkpoint inhibitor. That is, when the protein amount of one or more biomarkers selected from the group consisting of HRG, AZGP1, complement C5, IHKV4-1, MAN1A, A2M and HYOU1 is less than the cutoff value as a result of performing companion diagnosis predicting the reactivity of PD-1 immune checkpoint inhibitor and / or PD-L1 immune checkpoint inhibitor to cancer cells using the biomarker composition for companion diagnosis according to the present invention, the cancer cells may be highly responsive to the PD-1 immune checkpoint inhibitor and / or PD-L1 immune checkpoint inhibitor. In this case, the patient may be classified into a responder group that shows an effect of anti-cancer treatment through PD-1 immune checkpoint inhibitor and / or PD-L1 immune checkpoint inhibitor.

[0081] Meanwhile, the biomarker composition for companion diagnostics according to the present invention is characterized in that it is extracted from any one selected from the group consisting of blood, serum, plasma, and tissue. In addition, one of the effects of the present invention is that the present invention is capable of predicting the reactivity of one or more immune checkpoint inhibitors, including PD-1 immune checkpoint inhibitors and PD-L1 immune checkpoint inhibitors, through blood proteome analysis in addition to the conventional companion diagnosis through tissue.

[0082] That is, the biomarker composition for companion diagnostics according to the present invention is preferably extracted from blood, but is not limited thereto. More specifically, the biomarker composition for companion diagnostics according to the present invention has an effect of predicting the therapeutic response of at least one immune checkpoint inhibitor selected from the group consisting of PD-1 immune checkpoint inhibitor and PD-L1 immune checkpoint inhibitor by performing companion diagnosis through proteome analysis of the blood of a cancer patient.

[0083] In addition, the biomarker composition for companion diagnostics according to the present invention may be extracted from tissue as described above, in which case the protein expression level of the complement C7 can be measured through quantitative analysis. Meanwhile, when the biomarker composition for companion diagnostics according to the present invention is extracted from tissue, the protein expression level of the complement C7 is characterized by being reduced in a responder group of patients who are effective against anti-cancer treatment using a PD-1 immune checkpoint inhibitor, compared to a non-responder group of patients who are not effective against anti-cancer treatment using a PD-1 immune checkpoint inhibitor.

[0084] Conversely, when the biomarker composition for companion diagnostics according to the present invention is extracted from tissue, the complement C7 is characterized in that its protein expression level is increased in a non-responder patient group that is not effective against anti-cancer treatment using PD-1 immune checkpoint inhibitors compared to a responder patient group that is effective against anti-cancer treatment using PD-1 immune checkpoint inhibitors.

[0085] In addition, when the biomarker composition for companion diagnostics according to the present invention is extracted from tissue, the complement C7 is characterized in that the protein expression level is decreased in a patient group that responds to anti-cancer treatment using PD-L1 immune checkpoint inhibitors compared to a patient group that does not respond to anti-cancer treatment using PD-L1 immune checkpoint inhibitors. Conversely, when the companion diagnostic biomarker composition according to the present invention is extracted from tissue, the complement C7 is characterized in that its protein expression level is increased in a non-responder patient group that is not effective against anti-cancer treatment using PD-L1 immune checkpoint inhibitors compared to a responder patient group that is effective against anti-cancer treatment using PD-L1 immune checkpoint inhibitors.

[0086] Meanwhile, when the biomarker composition for companion diagnostics according to the present invention is extracted from tissue, one or more biomarkers selected from the group consisting of HRG, AZGP1, complement C5, IHKV4-1, MAN1A, A2M and HYOU1 are characterized in that their protein expression levels are decreased in a responder group of patients who are effective against anti-cancer treatment using PD-1 immune checkpoint inhibitors compared to a non-responder group of patients who are not effective against anti-cancer treatment using PD-1 immune checkpoint inhibitors.

[0087] Conversely, when the biomarker composition for companion diagnostics according to the present invention is extracted from tissue, one or more biomarkers selected from the group consisting of HRG, AZGP1, complement C5, IHKV4-1, MAN1A, A2M and HYOU1 are characterized in that their protein expression levels are increased in a non-responder patient group that is not effective against anti-cancer treatment using PD-1 immune checkpoint inhibitors compared to a responder patient group that is effective against anti-cancer treatment using PD-1 immune checkpoint inhibitors.

[0088] In addition, when the biomarker composition for companion diagnostics according to the present invention is extracted from tissue, one or more biomarkers selected from the group consisting of HRG, AZGP1, complement C5, IHKV4-1, MAN1A, A2M and HYOU1 are characterized in that their protein expression levels are decreased in a patient group that responds to anti-cancer treatment using PD-L1 immune checkpoint inhibitors compared to a patient group that does not respond to anti-cancer treatment using PD-L1 immune checkpoint inhibitors.

[0089] Conversely, when the biomarker composition for companion diagnostics according to the present invention is extracted from tissue, one or more biomarkers selected from the group consisting of HRG, AZGP1, complement C5, IHKV4-1, MAN1A, A2M and HYOU1 are characterized in that their protein expression levels are increased in a non-responder patient group that is not effective against anti-cancer treatment using PD-L1 immune checkpoint inhibitors compared to a responder patient group that is effective against anti-cancer treatment using PD-L1 immune checkpoint inhibitors.

[0090] In addition, when the biomarker composition for companion diagnostics according to the present invention is extracted from tissue, the biomarker composition for companion diagnostics according to the present invention may further contain PD-L1 (Programmed Death-Ligand 1) protein. Thus, in addition to measuring the expression level of the PD-L1 protein, the biomarker composition for companion diagnostics according to the present invention can predict the therapeutic response of a cancer patient to at least one immune checkpoint inhibitor selected from the group consisting of a PD-1 immune checkpoint inhibitor and a PD-L1 immune checkpoint inhibitor. Meanwhile, in the biomarker composition for companion diagnostics according to the present invention, the cancer cells are cancer cells corresponding to carcinomas that specifically react to one or more immune checkpoint inhibitors, among PD-1 immune checkpoint inhibitors and PD-L1 immune checkpoint inhibitors. That is, the present invention can perform companion diagnostics for any target carcinoma that can be treated with anti-cancer treatment through one or more immune checkpoint inhibitors, among PD-1 immune checkpoint inhibitors and PD-L1 immune checkpoint inhibitors.

[0091] In addition, in the biomarker composition for companion diagnostics according to the present invention, the cancer cells are cancer cells corresponding to any one of the carcinomas selected from the group consisting of lung cancer, liver cancer, gastric cancer, gastroesophageal junction adenocarcinoma, skin melanoma, head and neck cancer, bone cancer, pancreatic cancer, skin cancer, uterine cancer, ovarian cancer, rectal cancer, colon cancer, colon cancer, breast cancer, uterine sarcoma, trumpeteran duct carcinoma, endometrial carcinoma, cervical carcinoma, vaginal carcinoma, vulvar carcinoma, esophageal cancer, laryngeal cancer, small intestine cancer, thyroid cancer, parathyroid cancer, soft tissue sarcoma, urethral cancer, penile cancer, prostate cancer, chronic or acute leukemia, solid tumor of childhood, differentiated lymphoma, bladder cancer, kidney cancer, renal cell carcinoma, renal pelvic carcinoma, primary central nervous system lymphoma, spinal cord tumor, brain stem glioma, and pituitary adenoma.

[0092] More specifically, in the biomarker composition for companion diagnostics according to the present invention, the cancer cells are preferably cancer cells corresponding to lung cancer or liver cancer, but are not limited thereto.

[0093] Meanwhile, the biomarker composition for companion diagnostics according to the present invention is characterized in that it is administered simultaneously or sequentially in combination with any one or more immune checkpoint inhibitors selected from a PD-1 immune checkpoint inhibitor and a PD-L1 immune checkpoint inhibitor.

[0094] <Companion diagnostic kit> Meanwhile, the present specification further discloses a companion diagnostic kit comprising a companion diagnostic biomarker composition that contains Complement Component C7 and predicts the reactivity of one or more immune checkpoint inhibitors, including a PD-1 checkpoint inhibitor and a PD-L1 checkpoint inhibitor, against cancer cells. In the companion diagnostic kit according to the present invention, matters related to the companion diagnostic biomarker composition are the same as those in the above-mentioned <Companion diagnostic biomarker composition>. A companion diagnostic kit according to the present invention may comprise a companion diagnostic biomarker composition according to the present invention.

[0095] The companion diagnostic kit according to the present invention is preferably any one selected from the group consisting of an ELISA (Enzyme Linked Immunosorbent Assay) kit, a protein chip kit, a Rapid kit, and an MRM (Multiple Reaction Monitoring) kit, but is not limited thereto. In this case, any one selected from the group consisting of an ELISA kit, a protein chip kit, a Rapid kit, and an MRM (Multiple Reaction Monitoring) kit may be a kit performed by a known method.

[0096] Additionally, the companion diagnostic kit according to the present invention may further comprise one or more other component compositions, solutions or devices suitable for the analytical method.

[0097] The companion diagnostic kit according to the present invention may be a diagnostic kit characterized by including essential elements required for performing ELISA. The ELISA kit may include an antibody, an interacting protein, a ligand, nanoparticles, or an aptamer that specifically binds to the protein or peptide fragment. The antibody has high specificity and affinity for each complement protein and has almost no cross-reactivity with other proteins, and may be a monoclonal antibody, a polyclonal antibody, or a recombinant antibody. The ELISA kit may also include an interacting protein, a ligand, nanoparticles, an aptamer, or an antibody specific to a control protein that specifically binds to the protein or peptide fragment. In addition, the ELISA kit may include a reagent capable of detecting the bound antibody, such as a labeled secondary antibody, a chromophore, an enzyme (e.g., an enzyme conjugated with an antibody) and its substrate, or another substance that can bind to the antibody.

[0098] The claims of this specification will be described in more detail with reference to the accompanying drawings and examples. However, the drawings, examples, etc. presented in this specification can be modified in various ways by ordinary skilled artisans to have various forms, and the descriptions in this specification should not be considered as limiting the present invention to a specific disclosed form, but as including all equivalents or alternatives within the spirit and technical scope of the present invention. In addition, the accompanying drawings are presented to help ordinary skilled artisans understand the present invention more accurately, and may be illustrated exaggerated or reduced in size.

[0099] {Examples and Evaluation} Example 1. Selection of nine companion diagnostic biomarkers including complement C7 Nine biomarker candidates to be included in the biomarker composition for companion diagnostics according to the present invention were selected through data mining, and the validation stage was carried out on the nine selected biomarker candidates.

[0100] Ten blood samples (hereinafter referred to as "Training Set") were prepared from lung cancer patients whose reactivity to PD-1 or PD-L1 immune checkpoint inhibitors against cancer cells had already been determined. Here, the ten blood samples were eight blood samples from responder patients (Responders) who showed an effect on anti-cancer treatment using PD-1 or PD-L1 immune checkpoint inhibitors, and two blood samples from non-responder patients (Non-Responders; Progressive Disease, PD) who showed no effect on anti-cancer treatment using PD-1 or PD-L1 immune checkpoint inhibitors. In addition, the eight blood samples from the responder group (Responders) who showed effectiveness against anti-cancer treatment using PD-1 or PD-L1 immune checkpoint inhibitors were classified into five blood samples from the responder group (Partial Response, PR) who showed a high effectiveness against anti-cancer treatment using PD-1 or PD-L1 immune checkpoint inhibitors, and three blood samples from the responder group (Stable Disease, SD) who showed a low effectiveness against anti-cancer treatment using PD-1 or PD-L1 immune checkpoint inhibitors.

[0101] Specific information on 10 blood samples in which the reactivity of PD-1 immune checkpoint inhibitors or PD-L1 immune checkpoint inhibitors to cancer cells of lung cancer patients has already been determined is shown in Table 1 below. In Table 1 below, PD means a non-response patient group that does not show an effect on anti-cancer treatment through PD-1 immune checkpoint inhibitors or PD-L1 immune checkpoint inhibitors, PR means a responder patient group that shows a high effect on anti-cancer treatment through PD-1 immune checkpoint inhibitors or PD-L1 immune checkpoint inhibitors, and SD means a responder patient group that shows a low effect on anti-cancer treatment through PD-1 immune checkpoint inhibitors or PD-L1 immune checkpoint inhibitors. In addition, in Table 1 below, M means male, and F means female.

[0102] [Table 1]

[0103] In order to predict the reactivity of PD-1 immune checkpoint inhibitors or PD-L1 immune checkpoint inhibitors to 10 blood samples in which the reactivity of PD-1 immune checkpoint inhibitors or PD-L1 immune checkpoint inhibitors to cancer cells of lung cancer patients has already been determined, plasma was extracted from each of the 10 blood samples, and after a pretreatment process, proteome analysis was performed on the 10 plasma samples using TMT10 isobaric compounds to measure the protein amounts of the 9 selected biomarker candidates, respectively. Here, the protein analysis was performed by quantitative analysis to measure the protein amounts of the 9 biomarker candidates, respectively.

[0104] In this case, the cutoff value of the protein amount measured for each of the nine types of biomarker candidates was set to 100 μg / mL, and when the protein amounts of the nine types of biomarker candidates were equal to or greater than the cutoff value, the patients were classified into a non-responder group (Non-Responder; Progressive Disease, PD) that did not show any effect on anti-cancer treatment via PD-1 immune checkpoint inhibitors or PD-L1 immune checkpoint inhibitors, and when the protein amounts of the nine types of biomarker candidates were less than the cutoff value, the patients were classified into a responder group (Partial Response, PR) that showed a high effect on anti-cancer treatment via PD-1 immune checkpoint inhibitors or PD-L1 immune checkpoint inhibitors and a responder group (Stable Disease, SD) that showed a low effect on anti-cancer treatment via PD-1 immune checkpoint inhibitors or PD-L1 immune checkpoint inhibitors, based on the protein measurement amounts of the nine types of biomarker candidates (hereinafter referred to as "Example 1").

[0105] Evaluation 1. Efficacy evaluation of a companion diagnostic biomarker composition containing complement C7 Figures 1a to 1i are graphs showing the companion diagnostic results predicting the reactivity of one or more of the immune checkpoint inhibitors, namely PD-1 immune checkpoint inhibitors and PD-L1 immune checkpoint inhibitors, against cancer cells for nine companion diagnostic biomarkers, namely complement C7, HRG, AZGP1, complement C5, IGKV4-1, MAN1A, A2M, SPP1 and HYOU1, respectively.

[0106] More specifically, Figure 1a is a graph showing the companion diagnostic results predicting the responsiveness of PD-1 immune checkpoint inhibitors to cancer cells for biomarker C7, Figure 1b is a graph showing the biomarker HRG, Figure 1c is a graph showing the biomarker AZGP1, Figure 1d is a graph showing the biomarker C5, Figure 1e is a graph showing the biomarker IGKV4-1, Figure 1f is a graph showing the biomarker MAN1A, Figure 1g is a graph showing the biomarker A2M, Figure 1h is a graph showing the biomarker SPP1, and Figure 1i is a graph showing the companion diagnostic results predicting the responsiveness of PD-1 immune checkpoint inhibitors to cancer cells for biomarker HYOU1.

[0107] 1, the protein analysis results for 10 types of blood samples show that the measured amount of the biomarker protein is constant even after several days, and that the companion diagnostic result of biomarker C7, which shows a certain tendency when the protein amount of the biomarker is equal to or greater than the cutoff value and when the protein amount of the biomarker is less than the cutoff value, is the best. Therefore, biomarker C7 is specified as a biomarker composition for companion diagnostics according to the present invention, and it can be presumed that the remaining biomarkers HRG, AZGP1, C5, IHKV4-1, MAN1A, A2M, and HYOU1, when used in combination with C7, show excellent companion diagnostic results as the biomarker composition according to the present invention.

[0108] Example 2. Companion diagnostic test using a companion diagnostic biomarker composition according to the present invention Based on the results of Example 1, 11 types of blood samples (hereinafter referred to as "Validation Set") of lung cancer patients were prepared, and plasma was extracted from each of the 11 types of blood samples, and then a pretreatment process was performed. Then, proteome analysis was performed on the 11 types of plasma using TMT10 isobaric compounds to measure the amount of protein for the complement C7. Here, the protein analysis was performed by quantitative analysis to measure the amount of protein for the complement C7.

[0109] Specific information on the 11 types of blood samples from lung cancer patients is shown in Table 2 below. In Table 2 below, PD means a non-response patient group that does not show an effect on anti-cancer treatment through PD-1 immune checkpoint inhibitors or PD-L1 immune checkpoint inhibitors, PR means a responder patient group that shows a high effect on anti-cancer treatment through PD-1 immune checkpoint inhibitors or PD-L1 immune checkpoint inhibitors, and SD means a responder patient group that shows a low effect on anti-cancer treatment through PD-1 immune checkpoint inhibitors or PD-L1 immune checkpoint inhibitors. In addition, in Table 2 below, M stands for male, and F stands for female.

[0110] [Table 2]

[0111] In this case, the cutoff value of the protein amount for measuring the complement C7 was set to 100 μg / mL, and when the protein amount of the complement C7 was equal to or greater than the cutoff value, the patients were classified into a non-responder group (Non-Responder; Progressive Disease, PD) that did not respond to anti-cancer treatment using PD-1 immune checkpoint inhibitors or PD-L1 immune checkpoint inhibitors, whereas when the protein amount of the complement C7 was less than the cutoff value, the patients were classified into a responder group (Partial Response, PR) that responded highly to anti-cancer treatment using PD-1 immune checkpoint inhibitors or PD-L1 immune checkpoint inhibitors, and a responder group (Stable Disease, SD) that responded poorly to anti-cancer treatment using PD-1 immune checkpoint inhibitors or PD-L1 immune checkpoint inhibitors, based on the measured protein amount of the complement C7 (hereinafter referred to as "Example 2").

[0112] Evaluation 2. Analysis and evaluation of companion diagnostic test results through the companion diagnostic biomarker composition according to the present invention Figure 2a is a graph showing the results of a companion diagnostic test for 10 lung cancer patients using a companion diagnostic biomarker composition according to an embodiment of the present invention, Figure 2b is a graph showing the results of a companion diagnostic test for 11 lung cancer patients using a companion diagnostic biomarker composition according to an embodiment of the present invention, and Figure 2c is a graph showing the results of a companion diagnostic test for a total of 21 lung cancer patients using a companion diagnostic biomarker composition according to an embodiment of the present invention.

[0113] More specifically, FIG. 2a shows the companion diagnostic test results using biomarker C7 in the training set of Example 1, FIG. 2b shows the companion diagnostic test results using complement C7 in the validation set of Example 2, and FIG. 2c shows the final results combining the companion diagnostic test results using biomarker C7 in the training set of Example 1 and the companion diagnostic test results using complement C7 in the validation set of Example 2.

[0114] Referring to FIG. 2, it can be confirmed that the companion diagnostic test results using the companion diagnostic biomarker composition according to the present invention for the 11 types of blood samples from lung cancer patients in Example 2 can accurately classify patients into a non-responder (Progressive Disease, PD) group that does not show an effect on anti-cancer treatment with PD-1 immune checkpoint inhibitors or PD-L1 immune checkpoint inhibitors, a responder (Partial Response, PR) group that shows a high effect on anti-cancer treatment with PD-1 immune checkpoint inhibitors or PD-L1 immune checkpoint inhibitors, and a responder (Stable Disease, SD) group that shows a low effect on anti-cancer treatment with PD-1 immune checkpoint inhibitors or PD-L1 immune checkpoint inhibitors, based on the cutoff value according to the protein amount of the complement C7.

[0115] In other words, the biomarker composition for companion diagnostics according to the present invention contains complement C7, and thus has excellent effects in companion diagnostics for predicting the reactivity of PD-1 immune checkpoint inhibitors or PD-L1 immune checkpoint inhibitors against cancer cells.

[0116] Example 3. Companion diagnostic test using a companion diagnostic biomarker composition according to the present invention further comprising the biomarker IGKV4-1 In Example 1, ten blood samples (hereinafter referred to as "Training Set") were prepared in which the reactivity of PD-1 immune checkpoint inhibitors or PD-L1 immune checkpoint inhibitors to cancer cells of lung cancer patients had already been determined. The information on the ten blood samples was as described above in Example 1. In order to predict the reactivity of PD-1 immune checkpoint inhibitors or PD-L1 immune checkpoint inhibitors to the ten blood samples in which the reactivity of PD-1 immune checkpoint inhibitors or PD-L1 immune checkpoint inhibitors to cancer cells of lung cancer patients had already been determined, plasma was extracted from each of the ten blood samples, and after a pretreatment process, proteome analysis was performed on the ten plasma samples using TMT10 isobaric compounds to measure the protein amounts of the biomarkers complement C7 and IGKV4-1 (Immunoglobulin Kappa Variable 4-1). Here, the protein analysis was performed by quantitative analysis to measure the protein amounts of the biomarkers complement C7 and IGKV4-1.

[0117] In this case, the protein amount of complement C7 measured in each of the 10 types of plasma was divided by the protein amount of IGKV4-1 measured to obtain the relative ratio. According to the relative ratio, the patients were classified into a non-responder (Progressive Disease, PD) group that does not show an effect on anti-cancer treatment using PD-1 immune checkpoint inhibitors or PD-L1 immune checkpoint inhibitors, a responder (Partial Response, PR) group that shows a high effect on anti-cancer treatment using PD-1 immune checkpoint inhibitors or PD-L1 immune checkpoint inhibitors, and a responder (Stable Disease, SD) group that shows a low effect on anti-cancer treatment using PD-1 immune checkpoint inhibitors or PD-L1 immune checkpoint inhibitors (hereinafter referred to as "Example 3").

[0118] Evaluation 3. Analysis and evaluation of companion diagnostic tests using a companion diagnostic biomarker composition according to the present invention further comprising the biomarker IGKV4-1 FIG. 3 is a graph showing the results of a companion diagnostic test when the biomarker composition for companion diagnostics according to one embodiment of the present invention further contains the biomarker IGKV4-1.

[0119] 3, the results of the companion diagnostic test using the biomarker composition for companion diagnostics according to the present invention for the 10 blood samples of lung cancer patients in Example 3 show that the protein amount of complement C7 is divided by the protein amount of IGKV4-1, and the patients can be accurately classified into a non-responder (Progressive Disease, PD) group that does not show an effect on anti-cancer treatment using PD-1 immune checkpoint inhibitors or PD-L1 immune checkpoint inhibitors, a responder (Partial Response, PR) group that shows a high effect on anti-cancer treatment using PD-1 immune checkpoint inhibitors or PD-L1 immune checkpoint inhibitors, and a responder (Stable Disease, SD) group that shows a low effect on anti-cancer treatment using PD-1 immune checkpoint inhibitors or PD-L1 immune checkpoint inhibitors according to a certain standard value according to the relative ratio. That is, the results of Example 3 are consistent with the information for the 10 blood samples listed in Table 1 of Example 1.

[0120] That is, the biomarker composition for companion diagnostics according to the present invention not only has an excellent effect in companion diagnostics predicting the reactivity of PD-1 immune checkpoint inhibitors or PD-L1 immune checkpoint inhibitors against cancer cells by containing complement C7, but also has an even more excellent effect in companion diagnostics predicting the reactivity of PD-1 immune checkpoint inhibitors or PD-L1 immune checkpoint inhibitors against cancer cells when the biomarker composition for companion diagnostics according to the present invention further contains the biomarker IGKV4-1.

[0121] These results suggest that excellent companion diagnostic results as in Example 3 will be obtained not only when the complement C7 further contains the biomarker IGKV4-1, but also when the complement C7 further contains one or more biomarkers selected from the group consisting of HRG (Histidine-Rich Glycoprotein), AZGP1 (Zinc-Alpha-2-Glycoprotein), Complement Component C5 (Complement Component C5), MAN1A (Mannosyl-Oligosaccharide 1,2-Alpha-Mannosidase 1A), A2M (Alpha-2-Macroglobulin), SPP1 (Osteopontin) and HYOU1 (Hypoxia Up-Regulated Protein 1). This can be inferred from the commonality that HRG, AZGP1, complement C5, IHKV4-1, MAN1A, A2M and HYOU1 act as biomarkers to regulate the antigen-antibody immune response in the human body, and are proteins involved in immune response and lysis according to gene ontology classification.

[0122] Experimental Example 1. When the cutoff value for the measured amount of complement C7 protein in the biomarker composition for companion diagnostics according to the present invention is 100 μg / mL (compared to PD-L1 pharmDx test) 27 types of blood samples from lung cancer patients were prepared, and plasma was extracted from each of the 27 blood samples. After a pretreatment process, proteome analysis was performed on the 27 types of plasma using TMT10 isobaric compounds to measure the amount of protein for the complement C7. Here, the protein analysis was performed by quantitative analysis to measure the amount of protein for the complement C7.

[0123] In this case, the cutoff value of the protein amount for measuring the complement C7 was set to 100 μg / mL, and when the protein amount of the complement C7 was equal to or greater than the cutoff value, the patients were classified into a non-responder (Progressive Disease, PD) group that did not show any effect on anti-cancer treatment using one or more immune checkpoint inhibitors among PD-1 immune checkpoint inhibitors and PD-L1 immune checkpoint inhibitors, and when the protein amount of the complement C7 was less than the cutoff value, the patients were classified into a responder (Partial Response, PR) group that showed a high effect on anti-cancer treatment using one or more immune checkpoint inhibitors among PD-1 immune checkpoint inhibitors and PD-L1 immune checkpoint inhibitors, and a responder (Stable Disease, SD) group that showed a low effect on anti-cancer treatment using one or more immune checkpoint inhibitors among PD-1 immune checkpoint inhibitors and PD-L1 immune checkpoint inhibitors, according to the measured protein amount of the complement C7 (hereinafter referred to as "Experimental Example 1").

[0124] Experimental Example 2: When the cutoff value for the measured amount of complement C7 protein in the biomarker composition for companion diagnostics according to the present invention is 105 μg / mL (compared to PD-L1 pharmDx test) The experiment was performed in the same manner as in Experimental Example 1, except that the cutoff value of the protein amount measured for the complement C7 was set to 105 μg / mL. When the protein amount of the complement C7 was equal to or greater than the cutoff value, the patients were classified into a non-responder group (Progressive Disease, PD) that did not show any effect on anti-cancer treatment using one or more immune checkpoint inhibitors among PD-1 immune checkpoint inhibitors and PD-L1 immune checkpoint inhibitors. When the protein amount of the complement C7 was less than the cutoff value, the patients were classified into a responder group (Partial Response, PR) that showed a high effect on anti-cancer treatment using one or more immune checkpoint inhibitors among PD-1 immune checkpoint inhibitors and PD-L1 immune checkpoint inhibitors, and a responder group (Stable Disease, SD) that showed a low effect on anti-cancer treatment using one or more immune checkpoint inhibitors among PD-1 immune checkpoint inhibitors and PD-L1 immune checkpoint inhibitors, according to the measured protein amount of the complement C7 (hereinafter referred to as "Experimental Example 2").

[0125] Experimental Example 3: When the cutoff value for the measured amount of complement C7 protein in the biomarker composition for companion diagnostics according to the present invention is 110 μg / mL (compared to PD-L1 pharmDx test) The experiment was performed in the same manner as in Experimental Example 1, except that the cutoff value of the protein amount measured for the complement C7 was set to 110 μg / mL. When the protein amount of the complement C7 was equal to or greater than the cutoff value, the patients were classified into a non-responder group (Non-Responder; Progressive Disease, PD) that did not show any effect on anti-cancer treatment using one or more immune checkpoint inhibitors among PD-1 immune checkpoint inhibitors and PD-L1 immune checkpoint inhibitors. When the protein amount of the complement C7 was less than the cutoff value, the patients were classified into a responder group (Partial Response, PR) that showed a high effect on anti-cancer treatment using one or more immune checkpoint inhibitors among PD-1 immune checkpoint inhibitors and PD-L1 immune checkpoint inhibitors, and a responder group (Stable Disease, SD) that showed a low effect on anti-cancer treatment using one or more immune checkpoint inhibitors among PD-1 immune checkpoint inhibitors and PD-L1 immune checkpoint inhibitors, according to the measured protein amount of the complement C7 (hereinafter referred to as "Experimental Example 3").

[0126] Comparative Experiment Example 1. Companion diagnostic test using "PD-L1 pharmDx test" The PD-L1 pharmDx test (hereinafter referred to as "pharmDx") is a companion diagnostic test used to determine whether pembrolizumab effectively demonstrates anti-cancer effects as an immune anti-cancer drug in certain patients. Twenty-seven types of tissue samples from lung cancer patients in Experimental Example 1 were prepared, and PD-L1 (Programmed Cell Death Protein 1 Ligand) protein was qualitatively examined in the cancer cells in the biopsy tissue samples using DAKO's PD-L1 pharmDx product by immunohistochemical staining, and the expression rate of PD-L1 protein in the cancer cells was observed. After the PD-L1 pharmDx test, the stained slides were observed under an optical microscope to calculate the tumor proportion score (TPS), which is the percentage of effective tumor cells that show partial or total cell membrane staining. Patients with a TPS of ≥ 50% were classified as Partial Response (PR) patients who showed a high response to anti-cancer treatment with at least one of PD-1 and PD-L1 immune checkpoint inhibitors, patients with a TPS of 1-49% were classified as Stable Disease (SD) patients who showed a low response to anti-cancer treatment with at least one of PD-1 and PD-L1 immune checkpoint inhibitors, and patients with a TPS of < 1% were classified as Non-Responder (Progressive) patients who showed no response to anti-cancer treatment with at least one of PD-1 and PD-L1 immune checkpoint inhibitors. The patients were classified into two groups: PD (Patient's Disease, PD) (hereinafter referred to as "Comparative Experimental Example 1").

[0127] Evaluation 4. Analysis and evaluation of results from Experimental Examples 1 to 3 and Comparative Experimental Example 1 The following is a comparison and evaluation of the companion diagnostic test results of Experimental Examples 1 to 3 and Comparative Experimental Example 1 described above.

[0128] Table 3 below shows the results of the companion diagnostic test according to Experimental Examples 1 to 3 and Comparative Experimental Example 1. In Table 3 below, "Result" means the number of patients classified into the corresponding patient group (PR, PR+SD, PD) as a result of the corresponding experiment, and "Actual" means the number of patients actually classified into the corresponding patient group (PR, PR+SD, PD) regardless of the presence or absence of the corresponding experiment. In other words, "Result / Actual" means the ratio of the number of patients classified into the corresponding patient group as a result of the corresponding experiment to the number of patients actually classified into the corresponding patient group.

[0129] [Table 3]

[0130] Referring to Table 3, in the case of Comparative Experimental Example 1 corresponding to the PD-L1 pharmDx test, it can be seen that the accuracy of distinguishing between a responder patient group (Partial Response, PR) who shows a high effect to anti-cancer treatment using one or more immune checkpoint inhibitors, among PD-1 immune checkpoint inhibitors and PD-L1 immune checkpoint inhibitors, and a responder patient group (Stable Disease, SD) who shows a low effect to anti-cancer treatment using one or more immune checkpoint inhibitors, among PD-1 immune checkpoint inhibitors and PD-L1 immune checkpoint inhibitors, is relatively lower than that of Experimental Examples 1 to 3.

[0131] Meanwhile, in the case of Experimental Examples 1 to 3, the accuracy of the companion diagnostic test results using the biomarker composition for companion diagnostics according to the present invention in distinguishing non-responders (Progressive Disease, PD) who do not show an effect to anti-cancer treatment using one or more immune checkpoint inhibitors of PD-1 immune checkpoint inhibitors and PD-L1 immune checkpoint inhibitors tends to be relatively somewhat lower than that of Comparative Experimental Example 1, but it can be confirmed that the accuracy of distinguishing between responder patients (Partial Response, PR) who show a high effect to anti-cancer treatment using one or more immune checkpoint inhibitors of PD-1 immune checkpoint inhibitors and PD-L1 immune checkpoint inhibitors and responder patients (Stable Disease, SD) who show a low effect to anti-cancer treatment using one or more immune checkpoint inhibitors of PD-1 immune checkpoint inhibitors and PD-L1 immune checkpoint inhibitors is significantly higher than that of Comparative Experimental Example 1.

[0132] Therefore, in Experimental Examples 1 to 3, it can be confirmed that the companion diagnostic test results using the biomarker composition for companion diagnostics according to the present invention are more accurate than those of Comparative Experimental Example 1, which corresponds to the PD-L1 pharmDx test. Experimental Example 4: When the cutoff value for the measured amount of complement C7 protein in the biomarker composition for companion diagnostics according to the present invention is 100 μg / mL (compared to SP263)

[0133] Thirty-six types of blood samples from lung cancer patients were prepared, and plasma was extracted from each of the 36 blood samples. After a pretreatment process, proteome analysis was performed on the 36 types of plasma using TMT10 isobaric compounds to measure the amount of protein for the complement C7. Here, the protein analysis was performed by quantitative analysis to measure the amount of protein for the complement C7.

[0134] In this case, the cutoff value of the protein amount for measuring the complement C7 was set to 100 μg / mL, and when the protein amount of the complement C7 was equal to or greater than the cutoff value, the patients were classified into a non-responder group (Non-Responder; Progressive Disease, PD) that did not show any effect on anti-cancer treatment using one or more immune checkpoint inhibitors among PD-1 immune checkpoint inhibitors and PD-L1 immune checkpoint inhibitors, and when the protein amount of the complement C7 was less than the cutoff value, the patients were classified into a responder group (Partial Response, PR) that showed a high effect on anti-cancer treatment using one or more immune checkpoint inhibitors among PD-1 immune checkpoint inhibitors and PD-L1 immune checkpoint inhibitors, and a responder group (Stable Disease, SD) that showed a low effect on anti-cancer treatment using one or more immune checkpoint inhibitors among PD-1 immune checkpoint inhibitors and PD-L1 immune checkpoint inhibitors, according to the measured protein amount of the complement C7 (hereinafter referred to as "Experimental Example 4"). Experimental Example 5. When the cutoff value for the measured amount of complement C7 protein in the biomarker composition for companion diagnostics according to the present invention is 105 μg / mL (compared to SP263)

[0135] The experiment was performed in the same manner as in Experimental Example 4, except that the cutoff value of the protein amount measured for the complement C7 was set to 105 μg / mL. When the protein amount of the complement C7 was equal to or greater than the cutoff value, the patients were classified into a non-responder group (Non-Responder; Progressive Disease, PD) that did not show any effect on anti-cancer treatment using one or more immune checkpoint inhibitors among PD-1 immune checkpoint inhibitors and PD-L1 immune checkpoint inhibitors. When the protein amount of the complement C7 was less than the cutoff value, the patients were classified into a responder group (Partial Response, PR) that showed a high effect on anti-cancer treatment using one or more immune checkpoint inhibitors among PD-1 immune checkpoint inhibitors and PD-L1 immune checkpoint inhibitors, and a responder group (Stable Disease, SD) that showed a low effect on anti-cancer treatment using one or more immune checkpoint inhibitors among PD-1 immune checkpoint inhibitors and PD-L1 immune checkpoint inhibitors, according to the measured protein amount of the complement C7 (hereinafter referred to as "Experimental Example 5").

[0136] Experimental Example 6: When the cutoff value for the measured amount of complement C7 protein in the biomarker composition for companion diagnostics according to the present invention is 110 μg / mL (compared to SP263) The experiment was performed in the same manner as in Experimental Example 4, except that the cutoff value of the protein amount measured for the complement C7 was set to 110 μg / mL. When the protein amount of the complement C7 was equal to or greater than the cutoff value, the patients were classified into a non-responder group (Non-Responder; Progressive Disease, PD) that did not show any effect on anti-cancer treatment using one or more immune checkpoint inhibitors among PD-1 immune checkpoint inhibitors and PD-L1 immune checkpoint inhibitors. When the protein amount of the complement C7 was less than the cutoff value, the patients were classified into a responder group (Partial Response, PR) that showed a high effect on anti-cancer treatment using one or more immune checkpoint inhibitors among PD-1 immune checkpoint inhibitors and PD-L1 immune checkpoint inhibitors, and a responder group (Stable Disease, SD) that showed a low effect on anti-cancer treatment using one or more immune checkpoint inhibitors among PD-1 immune checkpoint inhibitors and PD-L1 immune checkpoint inhibitors, according to the measured protein amount of the complement C7 (hereinafter referred to as "Experimental Example 6").

[0137] Comparative Experiment Example 2. Companion diagnostic test using "VENTANA PD-L1 (SP263) Assay" The VENTANA PD-L1 (SP263) Assay (hereinafter referred to as "SP263") is a companion diagnostic test used to determine whether nivolumab effectively exerts anti-cancer effects as an immune anti-cancer agent in certain patients.

[0138] Thirty-six types of tissue samples from lung cancer patients in Experimental Example 1 were prepared, and the cancer cells in the biopsy tissue samples were qualitatively examined for PD-L1 (Programmed Cell Death Protein 1 Ligand) protein using VENTANA PD-L1 (SP263) Assay product from VENTANA using immunohistochemical staining, and the expression rate of PD-L1 protein in the cancer cells was observed. After the PD-L1 pharmDx test, the stained slides were observed under an optical microscope to calculate the tumor proportion score (TPS), which is the percentage of effective tumor cells that show partial or total cell membrane staining. Patients with a TPS of ≥ 10% were classified as Partial Response (PR) patients who showed a high response to anti-cancer treatment with at least one of PD-1 and PD-L1 immune checkpoint inhibitors, patients with a TPS of 1-9% were classified as Stable Disease (SD) patients who showed a low response to anti-cancer treatment with at least one of PD-1 and PD-L1 immune checkpoint inhibitors, and patients with a TPS of < 1% were classified as Non-Responder (Progressive) patients who showed no response to anti-cancer treatment with at least one of PD-1 and PD-L1 immune checkpoint inhibitors. The patients were classified into two groups: PD (Patient's Disease, PD) (hereinafter referred to as "Comparative Experimental Example 2").

[0139] Evaluation 5. Analysis and evaluation of results from Experimental Examples 4 to 6 and Comparative Experimental Example 2 The following is a comparison and evaluation of the companion diagnostic test results of Experimental Examples 4 to 6 and Comparative Experimental Example 2 described above.

[0140] Table 4 below shows the results of the companion diagnostic test according to Experimental Examples 4 to 6 and Comparative Experimental Example 2. In Table 4 below, "Result" refers to the number of patients classified into the corresponding patient group (PR, PR+SD, PD) as a result of the corresponding experiment, and "Actual" refers to the number of patients actually classified into the corresponding patient group (PR, PR+SD, PD) regardless of the presence or absence of the corresponding experiment. In other words, "Result / Actual" refers to the ratio of the number of patients classified into the corresponding patient group as a result of the corresponding experiment to the number of patients actually classified into the corresponding patient group.

[0141] [Table 4]

[0142] Referring to Table 4, in the case of Comparative Experimental Example 2 corresponding to the VENTANA PD-L1 (SP263) Assay, it can be seen that the accuracy of distinguishing between a responder group (Partial Response, PR) who shows a high effect in anti-cancer treatment using one or more immune checkpoint inhibitors of PD-1 immune checkpoint inhibitors and a responder group (Stable Disease, SD) who shows a low effect in anti-cancer treatment using one or more immune checkpoint inhibitors of PD-1 immune checkpoint inhibitors and PD-L1 immune checkpoint inhibitors is relatively lower than that of Experimental Examples 4 to 6. In addition, it can be seen that the accuracy of distinguishing a non-responder group (Non-Responder; Progressive Disease, PD) who does not show an effect in anti-cancer treatment using one or more immune checkpoint inhibitors of PD-1 immune checkpoint inhibitors and PD-L1 immune checkpoint inhibitors is also relatively lower than that of Experimental Examples 4 to 6.

[0143] On the contrary, in the case of Experimental Examples 4 to 6, it was confirmed that the accuracy of distinguishing the responder group (Partial Response, PR) who shows a high response to anti-cancer treatment using one or more immune checkpoint inhibitors of PD-1 immune checkpoint inhibitors and PD-L1 immune checkpoint inhibitors, the responder group (Stable Disease, SD) who shows a low response to anti-cancer treatment using one or more immune checkpoint inhibitors of PD-1 immune checkpoint inhibitors and PD-L1 immune checkpoint inhibitors, and the non-responder group (Non-Responder; Progressive Disease, PD) who does not show an effect to anti-cancer treatment using one or more immune checkpoint inhibitors of PD-1 immune checkpoint inhibitors and PD-L1 immune checkpoint inhibitors, based on the companion diagnostic test results using the biomarker composition for companion diagnostics according to the present invention, is relatively higher than that of Comparative Experimental Example 2.

[0144] Therefore, in the case of Experimental Examples 4 to 6, it can be confirmed that the companion diagnostic test results using the biomarker composition for companion diagnostics according to the present invention are more accurate than those of Comparative Experimental Example 2 corresponding to the VENTANA PD-L1 (SP263) Assay.

[0145] The companion diagnostic biomarker composition of the present invention and the companion diagnostic kit including the same as described above have the effect of predicting the therapeutic response to one or more immune checkpoint inhibitors selected from PD-1 immune checkpoint inhibitors and PD-L1 immune checkpoint inhibitors through proteome analysis in the blood of cancer patients as well as companion diagnosis through the tissue of cancer patients.

[0146] In addition, the biomarker composition for companion diagnostics according to the present invention and the companion diagnostic kit including the same have the advantage of being highly accurate in distinguishing between a responder patient group who shows efficacy and a non-responder patient group who does not show efficacy in anti-cancer treatment using one or more immune checkpoint inhibitors selected from PD-1 immune checkpoint inhibitors and PD-L1 immune checkpoint inhibitors. In addition, the companion diagnostic biomarker composition according to the present invention and the companion diagnostic kit including the same have the effect of more accurately identifying patient groups suitable for anti-cancer treatment using one or more immune checkpoint inhibitors selected from the group consisting of PD-1 immune checkpoint inhibitors and PD-L1 immune checkpoint inhibitors.

[0147] The above description is merely an illustrative example of the technical concept of the present invention, and various modifications and variations may be made by a person having ordinary skill in the art to which the present invention pertains without departing from the essential characteristics of the present invention.

[0148] Therefore, the embodiments disclosed in the present invention are for illustrative purposes only and are not intended to limit the technical idea of ​​the present invention, and the scope of the technical idea of ​​the present invention is not limited by such embodiments. The scope of protection of the present invention should be interpreted according to the following claims, and all technical ideas within the scope equivalent thereto should be understood to be included in the scope of the present invention.

Claims

1. The present invention includes Complement Component C7, and predicts the reactivity of one or more immune checkpoint inhibitors, including a PD-1 (Programmed Cell Death Protein 1) immune checkpoint inhibitor and a PD-L1 (Programmed Death-Ligand 1) immune checkpoint inhibitor, against cancer cells; It is characterized in that it is extracted from blood, and The amount of the complement C7 protein is measured through a quantitative analysis. Companion diagnostic biomarker compositions.

2. The companion diagnostic biomarker composition includes histidine-rich glycoprotein (HRG), zinc-alpha-2-glycoprotein (AZGP1), complement component C5 (complement component C5), immunoglobulin Kappa variable 4-1 (IHKV4-1), mannosyl-oligosaccharide 1,2-alpha-mannosidase 1A (MAN1A), alpha-2-macroglobulin (A2M), osteopontin (SPP1), and hypoxia up-regulated mitochondrial protein (HYOU1). Protein 1) The companion diagnostic biomarker composition of claim 1 .

3. The amount of the complement C7 protein can be measured by a variety of methods, including protein mass spectrometry, protein chip analysis, immunoassay, ligand binding assay, MALDI-TOF (Matrix Desorption / Ionization Time of Flight Mass Spectrometry) analysis, SELDI-TOF (Surface Enhanced Laser Desorption / Ionization Time of Flight Mass Spectrometry) analysis, radioimmunoassay, radial immunodiffusion, Ouchterlony immunodiffusion, rocket immunoelectrophoresis, tissue immunostaining, complement fixation analysis, two-dimensional electrophoresis, liquid chromatography-mass spectrometry, and the like. The present invention is characterized in that the amount of the IgG1-related protein is measured by any one of the following methods: LC-MS (Liquid Chromatography-Mass Spectrometry, Liquid Crystalline Mass Spectrometry / Mass Spectrometry), LC-MS / MS (Liquid Chromatography-Mass Spectrometry / Mass Spectrometry), Western Blot, and ELISA (Enzyme Linked Immunosorbent Assay). The companion diagnostic biomarker composition of claim 1 .

4. The amount of complement C7 is reduced in a patient group that responds to anti-cancer treatment using the PD-1 immune checkpoint inhibitor compared to a patient group that does not respond to anti-cancer treatment using the PD-1 immune checkpoint inhibitor. The companion diagnostic biomarker composition of claim 1 .

5. The amount of complement C7 is increased in a non-responder patient group that is not effective against anti-cancer treatment using the PD-1 immune checkpoint inhibitor, compared to a responder patient group that is effective against anti-cancer treatment using the PD-1 immune checkpoint inhibitor. The companion diagnostic biomarker composition of claim 1 .

6. The amount of complement C7 is reduced in a patient group that responds to anti-cancer treatment using the PD-L1 immune checkpoint inhibitor compared to a patient group that does not respond to anti-cancer treatment using the PD-L1 immune checkpoint inhibitor. The companion diagnostic biomarker composition of claim 1 .

7. The amount of complement C7 is increased in a non-responder patient group that is not effective against anti-cancer treatment using the PD-L1 immune checkpoint inhibitor, compared to a responder patient group that is effective against anti-cancer treatment using the PD-L1 immune checkpoint inhibitor. The companion diagnostic biomarker composition of claim 1 .

8. The cutoff value for the amount of complement C7 protein is within the range of 100 to 110 μg / mL. The companion diagnostic biomarker composition of claim 1 .

9. When the amount of complement C7 protein is equal to or greater than the cutoff value, the reactivity of the PD-1 immune checkpoint inhibitor to the cancer cells is low. The companion diagnostic biomarker composition of claim 8.

10. When the amount of complement C7 protein is less than the cutoff value, the reactivity of the PD-1 immune checkpoint inhibitor to the cancer cells is high. The companion diagnostic biomarker composition of claim 8.

11. When the amount of complement C7 protein is equal to or greater than the cutoff value, the reactivity of the PD-L1 immune checkpoint inhibitor to the cancer cells is low. The companion diagnostic biomarker composition of claim 8.

12. When the amount of complement C7 protein is less than the cutoff value, the reactivity of the PD-L1 immune checkpoint inhibitor to the cancer cells is high. The companion diagnostic biomarker composition of claim 8.

13. The companion diagnostic biomarker composition further comprises a PD-L1 (Programmed Death-Ligand 1) protein. The companion diagnostic biomarker composition of claim 1 .

14. The cancer cells are cancer cells corresponding to a carcinoma that specifically reacts to at least one of the PD-1 immune checkpoint inhibitor and the PD-L1 immune checkpoint inhibitor. The companion diagnostic biomarker composition of claim 1 .

15. The cancer cells are cancer cells belonging to any one of the following cancer types: lung cancer, liver cancer, gastric cancer, gastric and gastroesophageal junction adenocarcinoma, skin melanoma, head and neck cancer, bone cancer, pancreatic cancer, skin cancer, uterine cancer, ovarian cancer, rectal cancer, colon cancer, colon cancer, breast cancer, uterine sarcoma, trumpeting duct carcinoma, endometrial carcinoma, cervical carcinoma, vaginal carcinoma, vulvar carcinoma, esophageal cancer, laryngeal cancer, small intestine cancer, thyroid cancer, parathyroid cancer, soft tissue sarcoma, urethral cancer, penile cancer, prostate cancer, chronic or acute leukemia, solid tumor of childhood, differentiated lymphoma, bladder cancer, kidney cancer, renal cell carcinoma, renal pelvic carcinoma, primary central nervous system lymphoma, spinal cord tumor, brain stem glioma, and pituitary adenoma. The companion diagnostic biomarker composition of claim 1 .

16. The cancer cells are characterized in that they are cancer cells corresponding to lung cancer or liver cancer. The companion diagnostic biomarker composition of claim 15.

Citation Information

Patent Citations

  • Methods and compositions for cancer treatment and treatment selection

    WO2016049385A1

  • Method for predicting efficacy of immune checkpoint inhibitor on test subject

    WO2018190379A1